Discontinued drugs in 2006: pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs.
This perspective is the second in a series discussing drugs dropped from development in 2006, with a focus on pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs. A survey of discontinued drugs from 2006 is provided, based on data from the Pharmaprojects database, along with an analysis of biology, mechanisms of action and economic considerations in developing new drugs.
Ozdemir
Cevdet
C
Marmara University, Division of Pediatric Allergy and Immunology, Istanbul, Turkey.
Akdis
Cezmi A
CA
D000818:Animals; D018926:Anti-Allergic Agents / Q000009:adverse effects / Q000592:standards*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000592:standards*; D003879:Dermatologic Agents / Q000009:adverse effects / Q000592:standards*; D017277:Drug Approval / Q000379:methods; D004345:Drug Industry / Q000379:methods / Q000592:standards; D015507:Drugs, Investigational / Q000009:adverse effects / Q000592:standards; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000592:standards*; D006801:Humans; D019141:Respiratory System Agents / Q000009:adverse effects / Q000592:standards*
D018926:Anti-Allergic Agents; D018501:Antirheumatic Agents; D003879:Dermatologic Agents; D015507:Drugs, Investigational; D005765:Gastrointestinal Agents; D019141:Respiratory System Agents